US EPA

2251648 

Journal Article 

Use of isosorbide dinitrate in status anginosus 

Semler, HJ 

1970 

Yes 

Current Therapeutic Research
ISSN: 0011-393X 

IPA/71/39125 

Ther 

REF 9 

789-793 

English 

4994683 

IPA COPYRIGHT: ASHP The purpose of this study was to use objective, noninvasive measures to investigate pathophysiologic mechanisms of status anginosus and to assess the role of isosorbide dinitrate (Sorbitrate) in their modification. Seventy-two patients received oral isosorbide dinitrate 10 mg. 3 times daily and at bedtime. Clinical response was based on a reduction in nitroglycerin requirements and/or frequency of attacks. Of the 42 patients who completed the study, 30 were males and most were 60-70 years of age. Patients generally manifested satisfactory clinical responses even when the angina was severe. Those factors commonly associated with a satisfactory response were: age above 50, the presence of hypertension, angina of less than 9 years' duration, the absence of angina at rest, and the presence of ECG abnormalities only after exercise. Isosorbide dinitrate was well tolerated by the majority of patients with only 9.5% experiencing side effects of headache, nausea, or dizziness. It was concluded that isosorbide dinitrate is a valuable agent for the treatment of severe angina pectoris and is safely tolerated by most patients with status anginosus.